133 related articles for article (PubMed ID: 32847480)
21. Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.
Baba H; Baba Y; Uemoto S; Yoshida K; Saiura A; Watanabe M; Maehara Y; Oki E; Ikeda Y; Matsuda H; Yamamoto M; Shimada M; Taketomi A; Unno M; Sugihara K; Ogata Y; Eguchi S; Kitano S; Shirouzu K; Saiki Y; Takamori H; Mori M; Hirata T; Wakabayashi G; Kokudo N
Oncotarget; 2015 Oct; 6(32):34004-13. PubMed ID: 26372896
[TBL] [Abstract][Full Text] [Related]
22. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Cunningham D; Lang I; Marcuello E; Lorusso V; Ocvirk J; Shin DB; Jonker D; Osborne S; Andre N; Waterkamp D; Saunders MP;
Lancet Oncol; 2013 Oct; 14(11):1077-1085. PubMed ID: 24028813
[TBL] [Abstract][Full Text] [Related]
24. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Braun MS; Richman SD; Thompson L; Daly CL; Meade AM; Adlard JW; Allan JM; Parmar MK; Quirke P; Seymour MT
J Clin Oncol; 2009 Nov; 27(33):5519-28. PubMed ID: 19858398
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
Larsen FO; Boisen MK; Fromm AL; Jensen BV
Acta Oncol; 2012 Feb; 51(2):231-3. PubMed ID: 21936753
[TBL] [Abstract][Full Text] [Related]
26. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ
Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654
[TBL] [Abstract][Full Text] [Related]
27. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Giessen C; von Weikersthal LF; Hinke A; Stintzing S; Kullmann F; Vehling-Kaiser U; Mayerle J; Bangerter M; Denzlinger C; Sieber M; Teschendorf C; Freiberg-Richter J; Schulz C; Modest DP; Moosmann N; Aubele P; Heinemann V
BMC Cancer; 2011 Aug; 11():367. PubMed ID: 21861888
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.
Buchler T; Pavlik T; Melichar B; Bortlicek Z; Usiakova Z; Dusek L; Kiss I; Kohoutek M; Benesova V; Vyzula R; Abrahamova J; Obermannova R
BMC Cancer; 2014 May; 14():323. PubMed ID: 24884897
[TBL] [Abstract][Full Text] [Related]
29. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
30. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
[TBL] [Abstract][Full Text] [Related]
31. Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial.
Tapia Rico G; Price T; Tebbutt N; Hardingham J; Lee C; Buizen L; Wilson K; Gebski V; Townsend A
Clin Colorectal Cancer; 2019 Jun; 18(2):141-148. PubMed ID: 30713134
[TBL] [Abstract][Full Text] [Related]
32. Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
Jackson CG; Sharples K; Thompson PI; O'Donnell A; Robinson BA; Perez DJ; Adams J; Isaacs R; Deva S; Hinder VA; Findlay MP
BMC Cancer; 2014 Oct; 14():737. PubMed ID: 25274181
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
Wong NS; Fernando NH; Bendell JC; Morse MA; Blobe GC; Honeycutt W; Pang H; Hurwitz HI
Clin Colorectal Cancer; 2011 Sep; 10(3):210-6. PubMed ID: 21855046
[TBL] [Abstract][Full Text] [Related]
34. Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Payette E; Sarker S; Chalchal H
Can J Rural Med; 2017; 22(4):148-152. PubMed ID: 28925914
[TBL] [Abstract][Full Text] [Related]
35. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Tol J; Koopman M; Rodenburg CJ; Cats A; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; Mol L; Antonini NF; Punt CJ
Ann Oncol; 2008 Apr; 19(4):734-8. PubMed ID: 18272912
[TBL] [Abstract][Full Text] [Related]
36. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
37. Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
De Bruijn MT; Raats DA; Tol J; Hinrichs J; Teerenstra S; Punt CJ; Rinkes IH; Kranenburg O
Anticancer Res; 2011 Apr; 31(4):1379-85. PubMed ID: 21508389
[TBL] [Abstract][Full Text] [Related]
38. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Koopman M; Antonini NF; Douma J; Wals J; Honkoop AH; Erdkamp FL; de Jong RS; Rodenburg CJ; Vreugdenhil G; Akkermans-Vogelaar JM; Punt CJ
Ann Oncol; 2006 Oct; 17(10):1523-8. PubMed ID: 16873425
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Ghiringhelli F; Bichard D; Limat S; Lorgis V; Vincent J; Borg C; Berthou J; Orry D; Ortega-Deballon P; Lakkis Z; Facy O; Heyd B; Rat P; Nerich V; Ladoire S
Ann Surg Oncol; 2014 May; 21(5):1632-40. PubMed ID: 24419756
[TBL] [Abstract][Full Text] [Related]
40. Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
Aravantinos G; Isaakidou A; Karantanos T; Sioziou A; Theodoropoulos GE; Pektasides D; Gazouli M
Cancer Biomark; 2015; 15(6):843-50. PubMed ID: 26406410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]